SCHEDULE: Sands Capital Discloses 5.3% Stake in Acrivon Therapeutics

Sands Capital entities and Frank M. Sands jointly report beneficial ownership of 5.3% of Acrivon Therapeutics' common stock as of June 30, 2026.

Summary

• Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC, and Frank M. Sands have jointly filed a Schedule 13G, indicating their beneficial ownership of Acrivon Therapeutics, Inc. common stock.
• As of June 30, 2026, the reporting persons collectively beneficially owned 2,289,271 shares, representing 5.3% of the class of securities.
• This ownership percentage is based on 42,853,362 shares outstanding as of August 7, 2026, as reported in Acrivon Therapeutics' Form 10-Q filed on August 12, 2026.
• The filing is an amendment (Amendment No. 4) to a previous Schedule 13G filing.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership percentage without new operational or financial disclosures.

Positives

• Significant institutional ownership by Sands Capital, suggesting confidence in the company's long-term prospects.
• The filing confirms a substantial stake, which can sometimes lead to increased investor interest.

Negatives

• The filing does not contain new operational or financial performance data, making it difficult to assess the company's current health.
• The reporting persons disclaim beneficial ownership beyond their pecuniary interest, which is standard but offers no additional insight into their strategic intent.

Risks

• The filing itself does not introduce new risks, but the underlying investment in Acrivon Therapeutics is subject to the risks disclosed in the company's other SEC filings.
• Changes in beneficial ownership, even if not indicative of a change in control, can sometimes precede other strategic moves by large shareholders.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Acrivon Therapeutics.

Management Comments

• Each Reporting Person and the Sands General Partners disclaim beneficial ownership of any securities beyond its pecuniary interest therein.

Industry Context

StockSavvy.ai notes that significant stake disclosures by established investment firms like Sands Capital are common in the biotechnology and life sciences sector, often indicating a belief in the company's technology or market potential. However, this filing is purely a reporting event and does not provide insight into Acrivon's specific pipeline progress or clinical trial results.

Comparison to Industry Standards

• The 5.3% ownership stake by Sands Capital is a notable position for an institutional investor in a publicly traded biotechnology company. Many institutional investors in this sector hold positions ranging from less than 1% to over 10%, depending on their investment strategy and conviction in the company's science and market opportunity.
• The joint filing structure involving a fund, its investment manager, and an individual is a standard practice for investment firms managing multiple entities or strategies.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's stake, which may be viewed positively by some, but it does not directly alter existing share value or rights.
• Management and Board: The presence of a substantial shareholder like Sands Capital may influence board composition or strategic decisions over time, though no immediate impact is indicated.
• Creditors and Suppliers: No direct impact is indicated by this ownership disclosure.

Next Steps

• Sands Capital will continue to monitor Acrivon Therapeutics' performance and strategic developments.
• Acrivon Therapeutics will continue its operations and report future financial and operational results in subsequent filings.

Key Dates

Keywords

Acrivon Therapeutics, Schedule 13G, Sands Capital, Beneficial Ownership, Institutional Investor, Common Stock, Investment Management